Perioperative Management of Antirheumatic Drugs Prior to Total Joint Arthroplasty

The American College of Rheumatology (ACR) and the American Association of Hip and Knee Surgeons (AAHKS) released updated guidelines for the perioperative management of antirheumatic medications among patients with rheumatic diseases undergoing elective total hip arthroplasty (THA)

The current version includes updates from the original recommendations released in 20172 and reflects advances in medications that rheumatologists can consider for the treatment of inflammatory arthritis (IA) and systemic lupus erythematosus (SLE).

The guidelines also take into account the increased risk for infection in patients with IA and SLE after total joint arthroplasty (TJA), along with the risk for disease flares, which can decrease quality of life and lead to organ damage in patients with severe SLE.

General recommendations are included for continuing disease-modifying antirheumatic drugs (DMARDs) through surgery and holding biologics and Janus kinase (JAK) inhibitors prior to surgery.

A separate set of recommendations is provided for patients with SLE, which offer specific guidance for continuing medications among patients with severe SLE and holding medications in nonsevere SLE.

With regard to holding medications prior to surgery, the authors noted, “For patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, or all SLE for whom antirheumatic therapy was held prior to undergoing [TJA], restarting the antirheumatic therapy once the wound shows evidence of healing, any sutures/staples are out, there is no significant swelling, erythema or drainage, and there is no ongoing nonsurgical site infection, which is typically about 14 days.”

References

  1. American College of Rheumatology & American Association of Hip and Knee Surgeons. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty: guideline summary. Updated March 17, 2022. Accessed April 4, 2022. https://www.rheumatology.org/Portals/0/Files/Perioperative-Management-Guideline-Summary.pdf
  2. Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplastyArthritis Care Res. Published online June 16, 2017. doi:10.1002/acr.23274